SecSonar.com

Incyte Corporation (INCY)

Incyte Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Incyte Corporation (INCY) is a Biotechnology company based in US with a market capitalization of $19.5B. Revenue grew 21.2% year-over-year and the company generated $1.4B in free cash flow. This page tracks INCY's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 2.62K employees · IPO Nov 4, 1993

Valuation

Valuation & price

$95.31 · as of May 17, 2026 · -18.4% vs 52w high

14.9

P/E ratio

Latest-FY diluted EPS

3.77

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$117$92.06$67.27Jul 25Dec 25Jul 26Jul 7, 25$67.27Jul 9, 25$68.72Jul 11, 25$68.59Jul 15, 25$68.25Jul 17, 25$68.94Jul 21, 25$67.38Jul 23, 25$70.69Jul 25, 25$70.20Jul 29, 25$77.38Jul 31, 25$74.89Aug 4, 25$78.04Aug 6, 25$77.65Aug 11, 25$79.19Aug 13, 25$85.85Aug 15, 25$86.92Aug 19, 25$85.46Aug 21, 25$86.53Aug 25, 25$84.76Aug 27, 25$84.84Aug 29, 25$84.61Sep 3, 25$86.96Sep 5, 25$86.64Sep 9, 25$85.60Sep 11, 25$86.17Sep 16, 25$83.90Sep 18, 25$86.00Sep 22, 25$84.73Sep 24, 25$84.16Sep 26, 25$82.70Sep 30, 25$84.81Oct 2, 25$86.28Oct 6, 25$87.23Oct 8, 25$85.38Oct 10, 25$83.80Oct 14, 25$85.96Oct 16, 25$87.31Oct 21, 25$87.30Oct 23, 25$89.31Oct 27, 25$93.08Oct 29, 25$90.18Oct 31, 25$93.48Nov 4, 25$102.92Nov 6, 25$105.20Nov 10, 25$105.98Nov 12, 25$108.26Nov 14, 25$104.15Nov 18, 25$103.89Nov 20, 25$101.76Nov 25, 25$105.55Nov 28, 25$104.46Dec 2, 25$101.44Dec 4, 25$100.46Dec 8, 25$96.70Dec 10, 25$95.17Dec 12, 25$95.41Dec 16, 25$97.03Dec 18, 25$97.31Dec 22, 25$100.71Dec 24, 25$100.44Dec 29, 25$99.29Jan 2, 26$101.42Jan 6, 26$106.66Jan 8, 26$105.92Jan 12, 26$106.33Jan 14, 26$105.95Jan 16, 26$106.21Jan 21, 26$104.67Jan 23, 26$101.99Jan 27, 26$103.47Jan 29, 26$101.08Feb 2, 26$102.67Feb 4, 26$102.60Feb 9, 26$109.03Feb 11, 26$98.84Feb 13, 26$101.10Feb 18, 26$102.99Feb 20, 26$101.32Feb 24, 26$101.05Feb 26, 26$100.09Mar 2, 26$100.04Mar 4, 26$98.86Mar 6, 26$95.94Mar 10, 26$96.02Mar 12, 26$92.03Mar 17, 26$94.22Mar 19, 26$92.95Mar 23, 26$90.45Mar 25, 26$92.23Mar 27, 26$90.30Mar 31, 26$94.12Apr 2, 26$95.93Apr 7, 26$93.69Apr 9, 26$96.96Apr 13, 26$95.55Apr 15, 26$97.10Apr 17, 26$97.82Apr 22, 26$96.74Apr 24, 26$94.65Apr 28, 26$97.74Apr 30, 26$95.27May 4, 26$97.14May 6, 26$99.85May 8, 26$98.56May 12, 26$99.13May 14, 26$97.63May 18, 26$95.19May 20, 26$97.08May 22, 26$97.16May 28, 26$97.50Jun 1, 26$95.59Jun 3, 26$97.98Jun 5, 26$102.38Jun 9, 26$103.23Jun 11, 26$107.83Jun 15, 26$101.98Jun 17, 26$98.99Jun 22, 26$103.66Jun 24, 26$108.46Jun 26, 26$113.75Jul 2, 26$116.86
$67.2752-week range$116.86
Loading valuation history…

Fundamentals

Key fundamentals

$19.5B

Market cap

21.2%

Revenue growth (YoY)

92.8%

Gross margin

$1.4B

Free cash flow (USD)

-$3.5B

Net debt

Net cash position

-5.8%

Share dilution

3/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$1.1BFY 2017$1.5BFY 2018$1.9BFY 2019$2.2BFY 2020$2.7BFY 2021$3.0BFY 2022$3.4BFY 2023$3.7BFY 2024$4.2BFY 2025$5.1B
$1.1B$5.1B

Free cash flow by year

2016 → 2025

FY 2016$184.5MFY 2017$-204.0MFY 2018$262.7MFY 2019$632.6MFY 2020$-312.0MFY 2021$568.5MFY 2022$892.1MFY 2023$449.0MFY 2024$249.1MFY 2025$1.4B
$184.5M$1.4B

Gross margin by year

2021 → 2025

FY 202194.9%FY 202293.9%FY 202393.1%FY 202492.6%FY 202592.8%
94.9%92.8%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

4

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 28, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventLitigation SettlementJun 22, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 9, 2026Filing
  • Insider sellInsider Sell $264KTray Thomas · Principal Accounting Officer · $263.9KJun 8, 2026Filing
  • 8-K eventAcquisition AnnouncedJun 8, 2026Filing
  • Insider sellInsider Sell $200KTray Thomas · Principal Accounting Officer · $199.7KMay 28, 2026Filing
  • Insider sellInsider Sell $1.4MClancy Paul J · Director · $1.4MMay 21, 2026Filing
  • 8-K eventEarnings ReleaseApr 28, 2026Filing
  • Quarterly report10-Q FiledApr 28, 2026Filing
  • Insider sellInsider Sell $1.8MCAGNONI PABLO J · President, Global Head of R&D · $1.8MApr 21, 2026Filing

Questions

Frequently asked questions

What is Incyte Corporation's market cap?

Incyte Corporation (INCY) has a market capitalization of $19.5B.

What is INCY's P/E ratio?

INCY trades at a price-to-earnings ratio of 14.9, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is INCY's price-to-book (P/B) ratio?

INCY trades at 3.77 times book value per share.

Are insiders buying INCY stock?

SEC Form 4 filings show no open-market insider buys at Incyte Corporation in the last 90 days (4 sells).

Same arena

Related companies in Biotechnology

MRNA

Moderna, Inc.

$19.3B

ROIV

Roivant Sciences Ltd.

$21.7B

GMAB

Genmab A/S

$16.3B

NBIX

Neurocrine Biosciences, Inc.

$15.9B

INSM

Insmed Incorporated

$23.3B

UTHR

United Therapeutics Corporation

$23.4B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.